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Ovarian clear cell carcinoma (OCCC) reportedly develops from endometrio-
sis. However, the molecular mechanism underlying its malignant progression
to OCCC remains elusive. This study aimed to identify an essential gene in
the malignant transformation of endometriosis to OCCC. We performed
RNA sequencing in formalin-fixed, paraffin-embedded (FFPE) tissues of
endometriosis (n = 9), atypical endometriosis (AtyEm) (n = 18), adjacent
endometriosis to OCCC (AdjEm) (n = 7), and OCCC (n = 17). We found
that tetraspanin 1 (TSPAN1) mRNA level was significantly increased by 2.4-
(DESeq2) and 3.4-fold (edgeR) in AtyEm and by 80.7- (DESeq2) and 101-
fold (edgeR) in OCCC relative to endometriosis. We confirmed that
TSPAN1 protein level was similarly overexpressed in OCCC tissues and cell
lines. In immortalized endometriosis cell lines, TSPAN1 overexpression
enhanced cell growth and invasion. Mechanistically, TSPAN1 triggered
AMP-activated protein kinase (AMPK) activity, promoting endometriosis
and cell growth. Upregulated levels of TSPAN1 are considered an early
event in the development of high-risk endometriosis that could progress to
ovarian cancer. Our study suggests the potential of TSPAN1 as a screening
candidate for high-risk endometriosis.
1. Introduction
Endometriosis, a benign gynecological disease, occurs
in 10% of women of reproductive age. In endometrio-
sis, endometrial cells exist outside of the endometrium
of the uterus, resulting in chronic pain and infertility
[1]. Although its cause is unknown, endometriosis is
considered to be related to genetics, environment,
immunology, angiogenesis, and endocrine disturbance
[2]. Similar to malignant tumors, endometriosis also
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has characteristics of heterogeneity, adhesion, invasion,
and metastasis in its benign form and can potentially
transform into malignant cancer [2]. An association
between endometriosis and ovarian cancer was initially
proposed in 1925 [3]. Transition from endometriosis to
ovarian cancer was confirmed in 1953 [4]. Meta-analy-
ses have reported that endometriosis is closely related
to an increased risk of ovarian cancers when it occurs
in its clear, endometrioid, and low-grade serous form
[5]. It is, therefore, important to screen for high-risk
endometriosis that could progress to cancer.
Ovarian clear cell carcinoma (OCCC) is a histologi-
cal subtype of ovarian carcinoma showing distinctive
epidemiological and clinical characteristics [6]. Among
early-stage ovarian cancer subtypes, OCCC has a
favorable prognosis. However, among advanced-stage
ovarian cancer subtypes, OCCC has a poor prognosis
due to resistance to antiplatinum and taxane-based
chemotherapy [7,8]. OCCC has differing prevalence
rates depending on race and ethnicity, and has greater
prevalence in Asia than in western countries [9,10]. A
significant increase in the OCCC prevalence may be
due to factors related to ovulation and menstruation
[11]. OCCC is often diagnosed at an early-stage, but it
occurs in young women with an average age of
55 years than high-grade serous ovarian carcinoma,
which usually occurs at an average age of 64 years
[9,12].
Ovarian clear cell carcinoma is a common cancer
that accounts for 40–50% of endometriosis-associated
ovarian cancers (EAOC) [13–15]. The histological pre-
cancerous lesion of OCCC is known as atypical
endometriosis (AtyEm) [13] and is observed in 12–
35% of ovarian endometriosis cases [2]. The transfor-
mation of endometriosis to malignant neoplasm
involves an intermediate endometriosis lesion, such as
AtyEm, and is further influenced by hormone levels,
oxidative stress, genetic alteration, and immune dys-
regulation [16]. Activation of the oncogenic KRAS and
PI3K pathways and inactivation of the tumor suppres-
sor genes PTEN and ARID1A may be the main patho-
genic mechanisms of this progression [17].
Accordingly, genetic mutations can explain their
occurrence [18,19]. In previous studies, gene expression
profiling has been conducted to understand the molec-
ular mechanisms associated with the transition from
endometriosis to OCCC [20,21]. However, these mech-
anisms have not yet been clearly explained.
In this study, we aimed to discover new mecha-
nisms associated with the transformation of
endometriosis to malignant OCCC. We sought to
screen for high-risk endometriosis and identify candi-
date genes that may serve as targets for preventive
treatment, thus blocking the progression of
endometriosis to cancerous tumors.
2. Materials and methods
2.1. Patients and tumor specimens
This study was approved by the Institutional Review
Board of Gangnam Severance Hospital (3-2015-0298;
Seoul, Republic of Korea). The experiments were
undertaken with each patient’s understanding and
written consent, which was following the Declaration
of Helsinki. All formalin-fixed, paraffin-embedded tis-
sue samples were provided by the Korea Gynaecologic
Cancer Bank through the Bio & Medical Technology
Development Program of the Korean Ministry of Edu-
cation, Science and Technology. For RNA sequencing,
the FFPE tissue blocks comprised endometriosis
(n = 9), AtyEm (n = 18), adjacent endometriosis to
OCCC (AdjEm) (n = 7), OCCC (n = 17), and ovarian
endometrioid carcinoma (OEC) (n = 12). For tissue
microarray (TMA), the FFPE tissue blocks comprised
endometriosis (n = 83), AtyEm (n = 13), AdjEm
(n = 4), OCCC (n = 51), and OEC (n = 53).
2.2. Laser-capture microdissection (LCM) and
RNA extraction
All FFPE tissue slides were stained with hematoxylin
and reviewed by an experienced gynecological patholo-
gist. The selected lesions from whole tissues were
excised by LCM. For LCM, the FFPE tissues were
sectioned and placed on slides with polyethylene
terephthalate membrane (Leica Microsystems Inc.,
Buffalo Grove, IL, USA). LCM was performed using
a Leica AS LMD laser microdissection system (Leica
Microsystems Inc.) according to the manufacturer’s
instructions. A RNeasy FFPE kit (Qiagen, Valencia,
CA, USA) was used to isolate total RNA from FFPE
tissues according to the manufacturer’s instructions.
2.3. Ion AmpliSeqTM transcriptome library
preparation
Total RNA was calculated as the percentage of RNA
fragments longer than 200 nt using smear analysis of
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). DNA samples were quantified using
a Qubit dsDNA HS Assay Kit (Life Technologies,
Carlsbad, CA, USA). An Ion AmpliSeqTM Transcrip-
tome library was constructed with the Ion Transcrip-
tome Human Gene Expression Kit (Life
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Technologies), as per the manufacturer’s protocol.
Total RNA (10 ng) was reverse transcribed to synthe-
size cDNA by random priming. The cDNA product
was used to amplify target genes using an Ion Ampli-
SeqTM Human Gene Expression Core Panel with an
Ion AmpliSeqTM Library Kit Plus. After primer diges-
tion, adapters and molecular barcodes were ligated to
the amplicons, followed by magnetic bead purification.
This library was amplified for five cycles and purified.
Amplicon size and DNA concentration were measured
using an Agilent High Sensitivity DNA Kit (Agilent
Technologies) according to the manufacturer’s recom-
mendation.
2.4. Ion proton sequencing
Sample emulsion PCR, emulsion breaking, and enrich-
ment were performed using an Ion PITM Template
OT2 200 Kit v3 (Life Technologies, Part #4488318
Rev. B.0) according to the manufacturer’s instructions.
Multiple barcoded libraries were combined with equal
molar ratios for one Ion PITM v2 chip. Two-pooled
Ion AmpliSeqTM Exome libraries were loaded onto a
single Ion PITM v2 chip. Five-pooled Ion AmpliSeqTM
Transcriptome libraries were loaded onto a single Ion
PITM v2 chip. Subsequent emulsion PCR and enrich-
ment of the sequencing beads of the pooled libraries
were performed using the Ion OneTouchTM system
(Life Technologies) within approximately 7 h, accord-
ing to the manufacturer’s protocol. Finally, 520 Flows
sequencing was done on the Ion PITM v2 chip using
Ion PITM Sequencing 200 Kit v3 (Life Technologies,
Part #4488315 Rev. B.0) on the Ion ProtonTM
sequencer (Life Technologies).
2.5. RNA sequencing read mapping and gene
expression analysis
RNA sequencing reads were mapped to the human
genome (hg19), and the read count for each gene was
calculated. Each gene was normalized using read
counts, and differentially expressed genes (DEGs) were
analyzed using DESeq2 and edgeR. The complete
datasets are available in the Gene Expression Omnibus
database under accession number GSE157153. To
obtain several candidate genes, we applied P-values
rather than adjusted P-values. Because there was no or
only one common gene when the fold change cut-offs
of > 2 and adjusted P-values of < 0.05 or < 0.1 condi-
tions were applied (Fig. S1). Consequently, we selected
the 14 common genes according to the cutoff (2-fold
and P-value < 0.05). A Venn diagram was drawn using
a website (http://bioinformatics.psb.ugent.be/webtools/
Venn/). A heat map was drawn as log values using
CLUSTER3.0 [22] and JAVA TREEVIEW [23].
2.6. Cell culture
TOV-21G, ES-2, NIH3T3, and HS-5 cell lines were
purchased from the American Type Culture Collection
(Manassas, VA). OVISE and OVTOKO cell lines were
purchased from the Japanese Collection of Research
Biosources Cell Bank (Osaka, Japan), the HEK293T
cell line was purchased from System Biosciences (SBI
Inc., Palo Alto, MA, USA), and the SNU-251 cell line
was purchased from the Korean Cell Line Bank
(Seoul, Republic of Korea). TOV-21G, OVISE,
OVTOKO, and SNU-251 cells were maintained in
RPMI1640 supplemented with 1% penicillin/strepto-
mycin. ES-2 cells were maintained in McCoy’s 5A
medium containing 10% FBS with 1% penicillin/strep-
tomycin. 6045_SV40, 9585_SV40, HEK293T, NIH3T3,
and HS-5 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 1%
penicillin/streptomycin. 6595 and 6866_SV40 cells were
maintained DMEM/F12 with 1% penicillin/strepto-
mycin. All cell lines were cultured at 37 °C in a 5%
CO2 atmosphere.
2.7. Plasmid construction and viral infection
For the generation of TSPAN1 stable cell lines, cDNA
encoding human TSPAN1 was amplified using the pri-
mer set 50-AAGCTAGCATGCAGTGCTTCAGC
TTC-30 (forward) and 50-TTGGATCCTTATTGTA-
GATTGCAGTA-30 (reverse). The amplified cDNA
was cloned into NheI/BamHI restriction sites of the
pCDH-Promoter-MCS-EF1 Lentivector (System Bio-
sciences, Mountain View, CA, USA), which has no
green fluorescence protein (GFP) sequence. GFP dele-
tion was conducted as follows: PCR products were




MCS-EF1 Lentivector templates were selected by the
restriction enzyme DpnI; and the empty Lentivector
was used as a control for the stable cell lines.
TSPAN1-expressing stable cell lines were generated
using the viral packaging plasmids composed of
pCMV delta and pMDG. Virus particles were col-
lected 48 h and 72 h post-transfection. Positively
infected cells were selected with 2 lgmL1 puromycin
(Sigma-Aldrich, St. Louis, MO, USA) for 15 days.
pLenti CMV/TO SV40 small + Large T vector and
human TERT were obtained from Addgene
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(Cambridge, MA, USA). HEK293T cells (1 9 106)
were co-transfected with 2 lg lentiviral vector and
2 lg pPACKH1 Lentivector Packaging Kit (System
Biosciences, Palo Alto). Crude virus supernatant
(total collected viral medium of 10 mL) was collected
48 and 72 h after transfection. Cells were infected
with 500 lL of the collected crude viral medium per
dish, and the medium was changed with fresh ones
after 24 h. During this process, the infected cells were
not used with a selection marker as described
previously [24].
2.8. siRNAs
TSPAN1 (#1157352), AMPK (#5562-1), ARID1A
(#8289-1, #8289-2), and negative control (#SN-1003)
knockdown were conducted using predesigned
siRNA sequences purchased from Bioneer (Daedeok-
gu, Daejeon, Republic of Korea). siTSPAN1 trans-
fection was performed using Lipofectamine RNAi-
Max (Thermo Scientific, Waltham, MA, USA), as
per the manufacturer’s instructions. siAMPK trans-
fection was carried out using G-Fectin (Genolution
Pharmaceuticals Inc., Seoul, Korea), as per the man-
ufacturer’s instructions.
2.9. Immunohistochemistry
Paraffin tissue sections were deparaffinized in two
changes of xylene, rehydrated in graded ethanol, and
treated for 30 min with 3% H2O2 solution in methanol
to block endogenous peroxidase activity. Then, the
sections were incubated with mouse monoclonal anti-
human TSPAN1 antibody (Santa Cruz Biotechnology,
Inc., Dallas, TX, USA; Cat# sc-376551) for 1 h at RT,
followed by detection using Dako LSAB+ (Dako,
Glostrup, Denmark). The reaction product was devel-
oped with 3,30-diaminobenzidine chromogen solution
(Dako). Sections were counterstained with hematoxylin
and mounted in Faramount aqueous mounting med-
ium (Dako). We used human small intestine tissue as
positive controls for TSPAN1 staining. TSPAN1 stain-
ing was confirmed at the cytoplasmic and apical mem-
brane of glandular cells (Fig. S2). TSPAN1 staining
was scored as positive when tumor or epithelial cells
showed cytoplasmic and membrane immunoreactivity.
It was performed by a gynecological pathologist.
TSPAN1 staining results were scored based on inten-
sity (0 = negative, 1 = weak, 2 = moderate, 3 = strong)
and the percentage of positive cells (0 = 0%, 1 = 1–
25%, 2 = 26–50%, 3 = 51–100%), as described previ-
ously [25].
2.10. Real-time and reverse transcription PCR
RNA extraction, cDNA synthesis, SYBR Green real-
time PCR, and quantification of mRNA were per-
formed as described previously [26]. Reverse transcrip-
tion PCR (RT-PCR) was performed with Real-taq
polymerase (RBC Bioscience, New Taipei City, Tai-
wan) and a PCR machine (Eppendorf, Hamburg, Ger-
many) according to the manufacturer’s instructions.
The PCR products were separated in 1% agarose gel
at 30 V for 30 min and detected using a Gel Doc
XR + imaging system (Bio-Rad Laboratories, Inc,
Hercules, CA, USA). The primers used real-time PCR
were as follows: for TSPAN1, forward 50-TGCCATG-
CAGTTTGTCAACG-30 and reverse 50-ACCATAG-
CAGCCCAGGAAAC-30; for GAPDH, forward
50-GAAGGTGAAGGTCGGAGTC-30 and reverse
50-GAAGATGGTGATGGGATTTC-30. The primers
used RT-PCR were as follows: TSPAN1, forward
50-AGCAAAAGGCTCACGACCAA-30 and reverse
50-CCCAATCACTGCTGCTTGCC-30; hTERT, for-
ward 50-GAGAACAAGCTGTTTGCGGG-30; and b-
actin, forward 50-CTCGCCTTTGCCGATCC-30 and
reverse 50-GGGGTACTTCAGGGTGAGGA-30.
hTERT, forward 5’-GAGAACAAGCTGTTTGCGGG-
3’ and reverse 5’-AAGTTCACCACGCAGCCATA-3’;
SV40 T, forward 5’-GCCCAGCCACTATAAG-
TACCA-3’, SV40 T and reverse 5’-CAAGCAACTC-
CAGCCATCCA-3’; b-actin, forward 5’-CTCGC
CTTTGCCGATCC-3’ and reverse 5’-GGGGTACTT-
CAGGGTGAGGA-3’.
2.11. Protein extraction and immunoblotting
Western blot analysis was conducted as described pre-
viously [24]. Anti-TSPAN1 (sc-376551), anti-a-Actinin
(sc-17829), anti-GAPDH (sc-59541), anti-Cytokeratin
7 (CK7; sc-23879), anti-Cytokeratin 18 (CK18; sc-
515852), anti-Progesterone Receptor (PR; sc-52), anti-
a-Actinin (sc-17829), and anti-ARID1A (sc-32761)
antibodies were obtained from Santa Cruz Biotechnol-
ogy, Inc, whereas anti-pAMPK (Thr172, #2535), anti-
pACC (Ser79, #11818), anti-ACC (#3662), anti-pAKT
(Ser473, #11818), anti-ACC (#3662), anti-pERK
(Thr202/Tyr204 #4370), and anti-ERK (#4695), anti-
Vimentin (#14472) and anti-estrogen receptor alpha
(ER-alpha; #13258) antibodies were purchased from
Cell Signaling Technology (Danvers, MA, USA). Anti-
AMPK alpha1 (#AF3197) was purchased from R&D
Systems (Minneapolis, MN, USA). Anti-estrogen
receptor beta (ER-beta; #PA1-310B) was obtained
from Thermo Scientific.
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2.12. Gene Expression Omnibus (GEO) dataset
analysis
Gene expression profiling data were obtained from the
published microarray data of the GSE53012,
GSE6008, GSE65986, and GSE29175 datasets from
GEO. Identification of differentially expressed
TSPAN1 was conducted with a sorting tool based on
MICROSOFT EXCEL software (Probe number: 209114_at
in affymetrix human U133A platform; Probe number:
ILMN_1747546 in Illumina HumanHT-12 V3.0
expression beadchip; Gene accession number:
NM_005727). Box plots and statistical analyses were
performed using GRAPHPAD PRISM 5 software (Graph-
Pad Software, Inc., La Jolla, CA, USA).
2.13. Immunofluorescence staining
6045_SV40 and 9585_SV40 cells were seeded in 24-well
cell culture plates until 30–40% confluence was
reached. Cells were rinsed with PBS, fixed with ice-
cold methanol for 1 h at RT, and washed three times
with PBS. The cells were incubated with TSPAN1
(1:100) with 1% bovine serum albumin in TBS con-
taining 0.1% Tween-20 (TBS-T) solution overnight at
4 °C. After three TBS-T washes, the cells were incu-
bated with anti-Mouse IgG conjugated to Alexa Fluor
488 dye (Cell Signaling) for 2 h at RT. Cells were
washed three times with TBS-T, and the nuclei were
labeled with 1 gmL1 Hoechst 33342 (Sigma-Aldrich)
for 10 min at RT. Cells were washed three times with
PBS for 5 min at RT. The cells were imaged using a
microscope (Life Technologies, EVOSFL Cell Imag-
ing System).
2.14. WST-1 assay
Cell proliferation was measured by WST assay (Daeil-
Lab, Seoul, Republic of Korea). Briefly, cells were
seeded at 0.1 9 104 viable cells per well onto 96-well
plates at a final volume of 100 lL per well. Cells were
incubated with WST-1 at 37 °C for 2 h, and optical
density (OD) values at 450 nm were recorded at days
0, 3, and 5 using a VERSA MaxTM (Bio-Rad Labora-
tories, Inc.). For drug treatment, 6045_SV40 stable
cells were seeded onto 96-well plates at a density of
0.08 9 104 viable cells per well in a final medium vol-
ume of 50 lL per well. After the cells were attached,
they were treated dimethyl sulfoxide (DMSO), wort-
mannin (Sigma-Aldrich), U0126 (Cell Signaling
#9903), and Compound C (Selleckchem, Houston, TX,
USA, S7306) with 50 lL medium. The medium with
the drug was changed twice within 7 days. Cells were
incubated with WST-1 at 37 °C for 2 h, and OD val-
ues at 450 nm were recorded using VERSA MaxTM
(Bio-Rad Laboratories, Inc.).
2.15. Crystal violet staining
Cells were seeded at 0.5–2 9 104 viable cells per well
onto 24-well plates. After the cells were attached, 20–
50 nM siTSPAN1, siAMPK alpha 1, or siControl was
transfected into them. Then, the cells were fixed using
10% acetic acid solution with 10% methanol at the
indicated times, stained with 0.5% crystal violet for
1 h, photographed, and extracted using 1% SDS solu-
tion. Crystal violet extract from the cells was measured
based on the absorbance at 595 nm with VERSA
MaxTM. All experiments were performed in triplicate.
2.16. Colony forming assay
For the long-term colony forming assay, cells were
seeded in 35-mm dish at a density of 0.3–0.6 9 104
viable cells per well, grown for 14 days, and fixed
using 10% acetic acid solution with 10% methanol.
For siRNA transfection, cells were seeded at 2 9 105
viable cells per well onto 6-well plates. Once cells were
attached, 50 nM siTSPAN1 and siControl were trans-
fected into the cells. After 24 h, the cells were detached
by trypsin-EDTA (Hyclone), reseeded onto 35-mm
dish, and incubated for 10 days. Crystal violet staining
was performed as mentioned above.
2.17. Cell invasion assay
A cell invasion assay was performed in an invasion
chamber (Neuro Probe 48-well Micro Chemotaxis
Chamber, Neuro Probe, Inc., Gaithersburg, MD,
USA) as described previously [27].
2.18. Endometriosis tissue and primary cell
culture
Ectopic endometrium tissue samples were obtained
from two patients who had histologically confirmed
endometriosis. Endometrium tissue samples were
obtained from two patients who did not have
endometriosis. This study was approved by the Institu-
tional Review Board of Gangnam Severance Hospital
(3-2019-0320). The experiments were undertaken with
each patient’s understanding and written consent,
which was following the Declaration of Helsinki.
Biopsy materials were stored in sterile saline at 4 °C
and transported to the laboratory. Fresh endometrial
biopsy specimens were washed with PBS, chopped into
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small pieces, and centrifuged for 5 min at 1000 g.
After the supernatant was discarded, the tissues were
incubated for 1 h at 37 °C in 1 mgmL1 of collage-
nase type IV. The dispersed cells were filtered through
a 50-lm cell strainer and were centrifuged for 5 min at
1000 g. The collected cells were suspended in 1 mL
DMEM/F12 or DMEM containing 10% FBS. Cells
were cultured in an incubator at 37 °C in a 5% CO2
atmosphere. Images of the gap in the monolayers were
captured (EVOSFL Cell Imaging System).
2.19. STR profiling
Genomic DNA of the four cells was extracted using
G-spinTM Total DNA Extraction Kit (iNtRON
Biotechnology, Seoul, Republic of Korea). For STR
profiling analysis, we assigned a cell line authentication
service (Cosmo Genetech, Seoul, Republic of Korea).
Genomic DNA was processed for STR profiling using
a PowerPlex 18D System (Promega, Madison, WI,
USA), according to the manufacturer’s instructions.
After PCR amplification, the samples were analyzed
using an ABI 3130xl Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA) and GENEMAPPER
v5.0 software (Applied Biosystems). STR matching
analysis was performed by Deutsche Sammlung von
Mikroorganismen und Zellkulturen (DSMZ; www.d
smz.de).
2.20. Growth curve and doubling time
To count the number of cells, cells were seeded in a 6-
well plate at a density of 3 9 104 cells per well, cul-
tured for 8 days, and counted every 2 days. Subse-
quently, 10 lL of resuspended cells was measured
using a LUNAIITM automated cell counter (Logos
Biosystems, Inc., Anyang, Republic of Korea). All
experiments were performed three times. The growth
rate was estimated between 2 and 8 days using a previ-
ously described formula [24].
2.21. Immunocytochemistry
Cells were seeded in a Lab-Tek Chamber slide (Nunc,
Rochester, NY, USA) and fixed with ice-cold metha-
nol. Endogenous peroxidase activity was quenched by
3% hydrogen peroxide solution for 10 min, and the
cells were washed three times in PBS. Nonspecific
binding was prevented by incubation with 5% bovine
serum albumin and 0.01% Triton X-100 with TBS for
15 min. The sections were then incubated with a 1 : 20
dilution of the anti-Fibroblast Marker antibody (Santa
Cruz Biotechnology, sc-73355) overnight at 4 °C.
Antibody binding was detected using incubation with
horseradish peroxidase-conjugated secondary antibody
at 37 °C for 1 h. Then, the sections were visualized by
3,30-diaminobenzidine solution (DakoKO, Seoul,
Republic of Korea), counterstained lightly with hema-
toxylin (Sigma-Aldrich), dehydrated with ethanol, and
observed using inverted microscopy (Carl Zeiss Medi-
tec AG, Suzhou, China).
2.22. Linear correlation by scatter plot
RNA sequencing reads were mapped to the human
genome (hg19), and the read counts for each gene were
calculated. Each gene was normalized using RPKM,
and linear correlation was analyzed though scatter
plots generated by the DNASTAR LASERGENE 15 software
(DNASTAR, Madison, WI, USA).
2.23. Statistical analysis
Results are expressed as the means  standard error
(SE). Unpaired t-tests were used to evaluate differences
between two groups of variables. IHC scoring data
was performed with Mann–Whitney test. Survival
curve analysis was performed using the Kaplan–Meier
method, and statistical significance was calculated
using the log-rank test. All analyses were carried out
with GRAPHPAD PRISM 5 software. Differences were con-
sidered significant at *P < 0.05, **P < 0.01,
***P < 0.001, #P > 0.05.
3. Results
3.1. Gene expression profiling via DESeq2 and
edgeR analysis
We obtained endometriosis and atypical endometrio-
sis tissues from non-OCCC patients. A total of 10
out of 17 OCCC patients had endometriosis around
the cancer tissues, and we obtained endometriosis
samples from 7 out of 10 OCCC with endometriosis
lesions and used as AdjEm. AdjEm is histologically
endometriosis; however, it is different from
endometriosis and AtyEm in that it coexists with
cancer tissues around it. Therefore, we included
AdjEm in this study as it could explain the progres-
sion of OCCC. mRNAs were extracted only from
the lesions excised from the FFPE tissues by LCM.
The clinical information of the samples is listed in
Table 1. The endometriosis group had the youngest
mean age of 28 years old, while the other three
groups had a mean age of 40. To identify the
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molecular changes responsible for the carcinogenic
transformation of endometriosis to OCCC, RNA
sequencing was performed. RNA sequencing results
were compared between each group according to the
linear correlation. Endometriosis and OCCC had the
lowest linear correlation (R2 = 0.8719), whereas
AtyEm and AdjEm had the highest linear correlation
(R2 = 0.9746) (Fig. S3). These results indicate that
AtyEm and AdjEm had the most similar gene pro-
files.
To enhance the accuracy of DEG analysis, both
DESeq2 and edgeR methods were used. DEGs were
analyzed in five comparison groups: endometriosis ver-
sus AtyEm, endometriosis versus AdjEm, endometrio-
sis versus OCCC, AtyEm versus OCCC, and AdjEm
versus OCCC excluding AtyEm versus AdjEm. Next,
to find the common DEGs in five comparison groups
a Venn diagram was used; 14 and 34 genes were iden-
tified by DESeq2 and edgeR analysis, respectively.
Then, 14 common genes were selected (i.e., TSPAN1,
EPCAM, TMEM84A, PKP3, ERBB3, MUC20,
B4GALNT3, B3GNT3, EPS8L1, KRT19, BSPRY,
SYTL1, SGK2, and CDK2P2) (Fig. 1A). The heat
map showed consistent increase in expression of all 14
genes from endometriosis to AtyEm and AdjEm and
finally to OCCC (Fig. 1B). Through normalization
counts (log2), the expression levels of 14 genes were
higher in AtyEm and AdjEm than endometriosis, and
in OCCC than AtyEm and AdjEm. All results were
statistically significant (Fig. 1C). Fold changes and P-
values for all comparisons are listed in Table S1. Com-
pared with endometriosis, TSPAN1 (DESeq2; 80.7-
fold, edgeR; 101-fold) had the most significant increase
in OCCC among the 14 genes.
3.2. TSPAN1 expression is high in OCCC
To explore the function of TSPAN1, we cultured pri-
mary endometrial and endometriosis cells. hTERT and
SV40 T antigens were expressed in these cells using
lentivirus, resulting in immortalized cell lines
(Fig. S4A) [28–30]. We identified the characteristics of
four immortalized cell lines. SV40 expression was con-
firmed in cell lines 6866, 6045, and 9585, which used
the SV40 T antigen (hereafter, 6866_SV40, 6045_SV40,
and 9585_SV40). However, there was no detectable
hTERT expression in the 6595 cell line using hTERT
(Fig. S4B). Despite failure to induce immortalization,
we used the 6595 cell line as a control for OCCC. The
6595 cell line grew the slowest than the cell lines
immortalized with SV40, indicated by the doubling
time (Fig. S4C). The expressions of the epithelial
markers CK7 and CK18 were confirmed in 6045_SV40
and 9585_SV40 cells, whereas expression of the proges-
terone receptor B, estrogen receptor alpha and beta,
and vimentin (Fig. S4D) were confirmed in all four cell
lines. As the fibroblast antigen protein (FAP) was not
detected by immunocytochemistry, fibroblasts were not
mixed in all cell lines. NIH3T3 and HS-5 were used as
positive control cells for FAP (Fig. S4E). Lastly, DNA
fingerprinting was performed in all four cell lines using
the 18 short tandem repeat (STR) loci, and the STR
profiles were compared using the Deutsche Sammlung
von Mikroorganismen und Zellkulturen database,
which confirmed that all four cell lines were novel
(Table S2).
We investigated the TSPAN1 mRNA and protein
expressions using our own endometrial cells (6595 and
6866_SV40), endometriosis cells (6045_SV40 and
Table 1. Clinical characteristics of patients.
Characteristic Endometriosis AtyEm AdjEm OCCC OEC
Number of cases
n (%) 9 (17.64) 18 (35.29) 7 (13.72) 17 (33.33) 12 (19.05)
Age at presentation (years)
Mean (SD) 27.78 (5.74) 40.00 (6.63) 44.57 (11.15) 43.59 (10.60) 48.50 (10.09)
FIGO stage, n (%)
I/II N/A N/A N/A 9 (41.17) 7 (58.33)
III/IV N/A N/A N/A 2 (11.76) 1 (8.33)
Recurrent N/A N/A N/A 4 (23.52) 1 (8.33)
Unknown N/A N/A N/A 2 (11.76) 3 (25.00)
Tumor grade, n (%)
Well + moderate N/A N/A N/A 0 (00.00) 7 (58.33)
Poor N/A N/A N/A 11 (64.70) 1 (8.33)
Unknown N/A N/A N/A 6 (35.29) 4 (33.33)
N/A, not applicable; SD, Std. Deviation.
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9585_SV40), and OCCC cells (ES-2, TOV-21G,
OVTOKO, and OVISE). TSPAN1 expression was
higher in OCCC cells (TOV-21G, OVTOKO, and
OVISE, but not ES-2) than in endometrial and
endometriosis cells (Fig. 2A). Immunohistochemistry
(Fig. 2B) confirmed that TSPAN1 protein expression
was higher in AtyEm and OCCC than in endometrio-
sis. However, there was no differential expression
between endometriosis and AdjEm or among AtyEm,
AdjEm, and OCCC cells (Fig. 2C). Additionally,
A C
B
Fig. 1. Identification of 14 upregulated genes by RNA sequencing. (A) Venn diagrams of the DEGs using DESeq2 and edgeR, based on five
two-group comparisons: Endometriosis versus AtyEm, Endometriosis versus AdjEm, Endometriosis versus OCCC, AtyEm versus OCCC,
and AdjEm versus OCCC. DEGs in the common intersection are identified by DESeq2 (14 genes, blue arrow) and edgeR (34 genes, red
arrow). Fourteen common genes were identified. (B) Heat map showing the expression of 14 genes in the four groups. (C) Individual gene
expression profiles of the 14 genes in four groups. Normalized read counts were obtained using DESeq2. Unpaired t-test was performed.
*P < 0.05, **P < 0.01, ***P < 0.001.
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TSPAN1 expression increased in stage I OCCC com-
pared to that in endometriosis, but there was no differ-
ence between stages in OCCC (Fig. 2D). According to
immunohistochemistry TSPAN1 analysis and patient
clinical information, only the diagnostic category was
statistically significant (P < 0.0001). The FIGO stage,
chemoresponse, and CA-125 had no statistical differ-
ences (Table S3). We also confirmed the tendency to
have a poor prognosis in overall survival, but it was
not statistically significant owing to the small sample
size (Fig. 2E).
TSPAN1 has a different expression level in ovarian
cancer subtypes. Mucinous and endometrioid subtypes
of ovarian cancer tissues have higher TSPAN1 expres-
sions than the serous subtype (n = 72) [31]. However,
it has not been reported that results compared
TSPAN1 expression levels in OCCC to other ovarian
cancer subtypes. We additionally obtained RNA
sequencing results of OEC. TSPAN1 mRNA analysis
revealed higher TSPAN1 expression in clear cell type
than in endometrioid types (P < 0.05) (Fig. 2F).
Immunohistochemistry scoring revealed similar
TSPAN1 protein expression (P < 0.05) (Fig. 2G).
These results are supported by the three GEO dataset
analysis (P < 0.05) (Fig. 2H–J).
3.3. TSPAN1 increase cell growth via AMPK
phosphorylation in endometriosis cell lines
To identify TSPAN1 function in endometriosis,
TSPAN1-overexpressing cell lines were produced using
6045_SV40 and 9585_SV40 cells. Each cell line was
infected with TSPAN1-overexpressing lentivirus and
an empty lentivirus (control). It was confirmed that
the overexpressing lines had higher TSPAN1 mRNA
and protein levels than the control. The expression
levels of the TSPAN1-overexpressing cell lines
decreased using siRNA (Fig. 3A,B). Immunofluores-
cence indicated TSPAN1 expression in the cytoplasm
of the transfected 6045_SV40 and 9585_SV40 stable
cell lines (Fig. 3C). To confirm that TSPAN1 affects
the cell growth rate, the short-term and long-term
effects on cell proliferation were examined in the
6045_SV40 and 9585_SV40 stable cell lines. TSPAN1-
overexpressing cells proliferated faster than the control
in 6045_SV40 and 9585_SV40 stable cell lines. The
9585_SV40 stable cells showed faster growth only
when tested for a long period of time (Fig. 3D,F).
Next, TSPAN1 knockdown reduced the growth rate of
the TSPAN1-overexpressing cell lines (Fig. 3E,G).
Furthermore, Matrigel invasion assay identified an
increase in invasion of 6045_SV40 stable cells in
response to TSPAN1, whereas 9585_SV40 stable cells
showed no change (Fig. 3H,I). These findings demon-
strated that TSPAN1 increased endometriosis cell
growth rate and affected cell invasion.
To determine the mechanism of growth and invasion
of endometriosis cells in response to TSPAN1, we
measured the phosphorylation of major kinases associ-
ated with cell growth and survival. TSPAN1 overex-
pression in the 6045_SV40 and 9585_SV40 stable cell
lines increased AMPK-Thr172 phosphorylation, which
was reduced upon siTSPAN1 treatment. However,
TSPAN1 expression did not induce a change in
pAKT-Ser473 and pERK-Thr201/Thr204 (Fig. 4A).
We treated the 6045_SV40 stable cell line with an
AKT upstream kinase PI3K inhibitor (wortmannin),
AMPK inhibitor (compound C), and ERK inhibitor
(U0126). Wortmannin and Compound C treatments
retarded the growth of the TSPAN1-overexpressing
cell lines, whereas U0126 treatment caused no change
(Fig. 4C). Next, wortmannin greatly reduced cell inva-
sion regardless of TSPAN1. When treated with U0126
and Compound C, TSPAN1-overexpressing cell inva-
sion did not decrease (Fig. 4D). Kinase activity was
confirmed by their phosphorylation levels. AMPK and
ERK activities were attenuated by their inhibitor, but
AKT activity was maintained regardless of its inhibitor
treatment (Fig. 4B). Wortmannin treatment did not
reduce AKT-Ser473 phosphorylation, but TSPAN1-in-
duced cell growth was attenuated. Therefore, it could
be speculated that TSPAN1 is involved in cell growth
through other PI3K pathways rather than PI3K/AKT
signaling.
Notably, Compound C reduced AMPK-Thr172
phosphorylation and TSPAN1-induced cell growth.
The crystal violet assay showed that the TSPAN1-in-
duced cell growth decreased depending on the Com-
pound C concentration (Fig. 4E,F). Finally, the cell
growth was assessed via the treatment of siAMPK
alpha1, which attenuates AMPK-Thr172 phosphoryla-
tion (Fig. 4G). The cell growth was accelerated in
siControl cells in response to TSPAN1, but AMPK
alpha1 knockdown cells showed no difference in
growth (Fig. 4H). These results suggest that TSPAN1
induces cell growth via AMPK phosphorylation in
endometriosis cells.
3.4. TSPAN1 knockdown reduce OCCC cell
growth via a mechanism not involving AMPK
To investigate whether TSPAN1 regulates the OCCC
growth, siTSPAN1 was transiently transfected into
TOV-21G and OVTOKO cells, followed by cell
growth measurements. Similar to endometriosis cells,
the growth rate of OCCC cell lines was delayed in
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response to reduced TSPAN1 expression (Fig. 5A–C).
However, unlike in endometriosis cells, in TOV-21G
and OVTOKO cells, siTSPAN1 did not cause a
change in AMPK-Thr172 phosphorylation compared
with the siControl (Fig. 5D). Next, we established a
TSPAN1-overexpressing TOV-21G cell line, which had
lower TSPAN1 levels than OVTOKO (Fig. S5A).
Consistent with the observation in siTSPAN1, while
there was a difference in cell growth in the long-term
experiment, there was no effect on AMPK-Thr172
phosphorylation when TSPAN1 was overexpressed
(Fig. S5B–D). We speculate that when cells have been
transformed into a malignant cell type such as OCCC,
TSPAN1 regulates cell growth via mechanisms other
than AMPK.
4. Discussion
Endometriosis is a common condition in young
women of childbearing age [1]. In the surgical treat-
ment of endometriosis, the ovaries are preserved
because of their relationship with the secretion of
female hormones [32]. However, as endometriosis may
lead to the development of ovarian cancer [2], pre-
emptive therapy is necessary through high-risk screen-
ing. Fortunately, because endometriosis tissue can be
obtained by a simple surgical method, it is easy to
apply pathological markers for endometriosis via tissue
immunostaining. Thus, it is necessary to observe gene
expression changes in endometriosis, AtyEm, AdjEm,
and OCCC via RNA sequencing.
We used AtyEm and AdjEm as an intermediate
stage between endometriosis and OCCC for RNA
sequencing analysis. According to the unsupervised
clustering results of the previously reported immune
genes (n = 511), AtyEm (85%) shows a similar
immune environment to cancer. This is because
AtyEm cells were homogeneously clustered closer to
EAOC than the endometrium [20]. OCCC-associated
endometriosis has abnormal gene expression that does
not occur in endometriosis without cancer tissues [21].
We also showed highest linear correlation between
AtyEm and AdjEm, and thus, the gene profiles of both
groups were similar. Therefore, AtyEm and AdjEm
exist in different environments and possess morpholog-
ical differences. By extension, we suggest that these are
intermediate stages representing gene changes, which
may explain the carcinogenic process of OCCC. Four-
teen common genes showing a pattern of a stepwise
increase in expression from endometriosis to OCCC,
while transitioning through AtyEm and AdjEm, can
be considered as potential candidate gene markers for
high-risk endometriosis screening.
TMA staining showed that TSPAN1 has higher
expression in AtyEm and early-stage OCCC than in
endometriosis (Fig. 2D). TSPAN1 therefore has poten-
tial as a pathological marker of high-risk endometrio-
sis. In addition, in this study, TSPAN1-overexpressing
endometriosis and OCCC cells had increased cell
growth compared to control cells. Conversely, inhibi-
tion of cell growth was observed upon TSPAN1
knockdown. TSPAN1, a member of the tetraspanin
family, is highly expressed in many types of cancer,
and increases cell growth, invasion, and migration in
colon, cervical, pancreatic, and prostate cancers [33–
36]. TSPAN1 reportedly plays a role in increasing
epithelial-to-mesenchymal transition and metastasis via
the PI3K/AKT pathway in cholangiocarcinoma [37].
The PI3K/AKT pathway is activated in endometriosis
[38,39], and together with the ERK pathway, it
enhances endometriotic stromal cell growth and sur-
vival [40]. However, in this study, TSPAN1-overex-
pressing endometriosis cells did not have altered AKT
and ERK activity, and their growth was promoted via
AMPK activation. AMPK activity has the function of
tumor suppression, which inhibits the anabolic process
that maintains cancer cell proliferation. Conversely,
AMPK has characteristics of a tumor promoter, allow-
ing cancer cells to survive in an environment of meta-
bolic stress or matrix detachment conditions. AMPK
Fig. 2. TSPAN1 is highly expressed in human OCCC cells and tissue specimens. (A) mRNA and protein levels of TSPAN1 were assessed
using RT-PCR (upper panel) and immunoblotting (lower panel) in cell lines. The expressions of b-actin and a-actinin were included as internal
loading controls. (B) Representative immunohistochemical staining images of TSPAN1 in FFPE tissues. Scale bar = 50 or 10 lm; 2009 or
10009 magnification. (C) Immunohistochemistry staining scores of TSPAN1 in Em, AtyEm, AdjEm, and OCCC. Data are expressed as the
mean  standard error (SE). Mann–Whitney test was performed. *P < 0.05, ***P < 0.001. (D) Immunohistochemistry staining scores of
TSPAN1 according to OCCC stage. Data are expressed as the mean  SE. Mann–Whitney test was performed. *P < 0.05, ***P < 0.001.
(E) Overall survival curves for OCCC (n = 42) according to TSPAN1 expression using Kaplan–Meier curve analysis. (F, G) TSPAN1 expression
as shown by RNA sequencing analyzed by DESeq2 and the immunohistochemical scoring scores in endometriosis, OCCC, and OEC.
*P < 0.05, **P < 0.01, ***P < 0.001. (H–J) mRNA expression levels of TSPAN1 were analyzed in an ovarian cancer cell line (GSE29175) and
ovarian cancer patient tissues (GSE6008 and GSE65986) in three GEO databases. Unpaired t-test was performed. *P < 0.05, **P < 0.01,
***P < 0.001.
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Fig. 3. TSPAN1 increases cell proliferation in endometriosis cell lines. (A) TSPAN1 expression was detected by real-time PCR (left panel)
and immunoblotting (right panel) in stable cell lines, with a-actinin as an internal loading control. Data are expressed as the
mean  standard error (SE); n = 3. Unpaired t-test was performed. ***P < 0.001. (B) TSPAN1 expression was detected by real-time PCR
(left panel) and immunoblotting (right panel) after transient transfection of siControl or siTSPAN1 in TSPAN1-overexpressed stable cell lines,
with a-actinin as an internal loading control. Data are expressed as the mean  SE; n = 3. Unpaired t-test was performed. ***P < 0.001. (C)
Immunofluorescent staining images of TSPAN1 (green) in stable cell lines. Nuclei are stained with Hoechst (blue). Scale bar = 100 lm,
4009 magnification. Cell proliferation was determined via WST-1 and (D) Crystal violet staining (E) at various times. Error bars represent
mean  SE; n = 3. Unpaired t-test was performed. **P < 0.01, ***P < 0.001. (F, G) Colony forming assay was performed for the cell lines.
Upper panel shows representative images; lower panel shows the relative absorbance at 595 nm. Error bars represent mean  SE; n = 3.
Unpaired t-test was performed. **P < 0.01, ***P < 0.001. H–I. Cell invasion analysis of stable cell lines using a Matrigel invasion assay.
Upper panel shows representative images (2009 magnification); lower panel shows quantification of invasion experiments. Results are
presented as the relative number of invading cells in five randomly selected fields. Error bars represent mean  SE; n = 3. Unpaired t-test
was performed. *P < 0.05, ***P < 0.001.
998 Molecular Oncology 15 (2021) 987–1004 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Tetraspanin 1 promotes endometriosis malignant transformation H.-T. SHIN et al.
A
E F G H
B C
D
Fig. 4. TSPAN1 increases cell growth through AMPK activity in the endometriosis cell line. (A) Protein levels were detected by
immunoblotting in stable cell lines, with a-actinin as an internal loading control (B) Protein levels were detected by immunoblotting after
treatment of inhibitors in 6045_SV40 stable cell lines. (DMSO: control; 500 nM wortmannin: PI3 kinase inhibitor; 5 lM U0126: ERK inhibitor;
1 lM Compound C: AMPK inhibitor), with a-actinin as an internal loading control. (C) Cell proliferation was determined via WST-1 after
treatment of inhibitors in 6045_SV40 stable cell lines. Unpaired t-test was performed. *P < 0.05, **P < 0.01, ***P < 0.001. (D) Cell invasion
analysis of stable cell lines using a Matrigel invasion assay after treating 6045_SV40 stable cells with inhibitors. Upper panel shows
quantification of invasion experiments (2009 magnification); lower panel shows representative images. Results are presented as the relative
number of invading cells in five randomly selected fields. Error bars represent mean  standard error (SE); n = 3. Unpaired t-test was
performed. *P < 0.05, ***P < 0.001. (E) Protein levels were confirmed by immunoblotting after treatment of DMSO and 0.5 and 1 lM of
Compound C in 6045_SV40 stable cell lines, with a-actinin as an internal loading control. (F) Cell proliferation was measured via crystal violet
assay after treatment of DMSO and 0.5 and 1 lM of Compound C in 6045_SV40 stable cells. Upper panel shows representative images;
lower panel shows the relative absorbance at 595 nm. Error bars represent mean  SE; n = 3 Unpaired t-test was performed. *P < 0.05,
**P < 0.01. (G) Protein expressions were detected by immunoblotting after transient transfection of siControl or siAMPK alpha1 in
6045_SV40 stable cells, with a-actinin as an internal loading control. (H) Cell proliferation was measured via crystal violet assay after
transient transfection of siControl or siAMPK alpha1 in 6045_SV40 stable cells. Upper panel shows representative images; lower panel
shows the relative absorbance at 595 nm. Data are expressed as the mean  SE; n = 3. Unpaired t-test was performed. ***P < 0.001.
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therefore exhibits a dual role in cancer survival [41,42].
The results of the current study demonstrate that
AMPK activity had a tumor-promoting function and
increased endometriosis cell growth in response to
TSPAN1.
As endometrial cells leave the uterus, they are
exposed to hypoxia. During this process, endometriosis
is formed through complex survival processes such as
steroidogenesis, angiogenesis, inflammation, and meta-
bolic switches [43]. To withstand the hypoxic condi-
tions, complex gene regulation is involved in
endometriosis development [43]. Hypoxia is the main
stimulus that activates AMPK [44,45]. AMPK
stimulates signaling essential for survival when cells
are exposed to a variety of stressful environments,
including hypoxia [46,47]. Therefore, AMPK may be
activated in endometriosis cells in various stressful
environments, thus affecting cell survival and growth.
We confirmed the TSPAN1 expression change in
hypoxic conditions through GSE53012 dataset [48]
analysis. When prostate cancer PC-3, ovarian cancer
SKOV3, and melanoma WM793B cells were exposed
to cycling (transient and intermittent) or chronic (pro-
longed) hypoxia, PC-3 and SKOV3 cells showed
higher TSPAN1 expression levels (Fig. S6). Collec-




Fig. 5. TSPAN1 knockdown decreases cell proliferation in OCCC cell lines. (A) TSPAN1 expression was detected by real-time PCR (left
panel) and immunoblotting (right panel) in TOV-21G and OVTOKO cells, with a-actinin as an internal loading control. Data are expressed as
the mean  standard error (SE); n = 3. Unpaired t-test was performed. *P < 0.05, **P < 0.01. (B) Cell proliferation was determined via
crystal violet staining at various times after transient transfection of siControl or siTSPAN1 in TOV-21G and OVTOKO cells. Error bars
represent mean  SE; n = 3. Unpaired t-test was performed. **P < 0.01, ***P < 0.001. (C) Colony forming assay was performed in TOV-
21G and OVTOKO cells. Upper panel shows representative images; lower panel shows the relative absorbance at 595 nm. Error bars
represent mean  SE; n = 3. Unpaired t-test was performed. **P < 0.01, ***P < 0.001. (D) Protein expressions were detected using
immunoblotting after transient transfection of siControl or siTSPAN1 in TOV-21G and OVTOKO cells, with a-actinin as an internal loading
control.
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are exposed to stressful environments, thus affecting
the endometriosis cell growth and invasion via AMPK
activation.
TSPAN1 knockdown in TOV-21G and OVTOKO
cells retarded cell growth. However, these cells exhib-
ited no change in AMPK activation compared with
endometriosis cells. Various gene mutations commonly
found in OCCC may explain why AMPK was not
activated by TSPAN1 in OCCC cells [17,49]. The
TOV-21G, OVTOKO, and OVISE cells used in this
study were OCCC cells with an ARID1A mutation
(Fig. S7A) [50]. It was confirmed that AMPK activity
(Thr172) was higher in OCCC cells than in
endometriosis cells (Fig. S7A). To investigate whether
AMPK activity is related to ARID1A mutation, we
decreased the level of ARID1A protein using siAR-
ID1A (Fig. S7B). When ARID1A was knocked down
in endometriosis cells, AMPK-Thr172 phosphorylation
was elevated, as shown in western blot analysis
(Fig. S7B). We thus confirmed that ARID1A mutation
regulated AMPK activity. Additionally, TOV-21G has
mutations in ARID1A, PIK3CA, PTEN, and KRAS.
Also, ES-2 has mutations in TP53 as well as KRAS,
downstream of BRAF, although it possessed wild-type
ARID1A [51]. KRAS and PTEN mutations maintain
cell growth by activating AMPK in astrocytic tumors
[52]. Therefore, we expect that AMPK activity is main-
tained at high levels in OCCC cells due to various
genetic mutations, AMPK activity does not further
increase with an increase in TSPAN1.
Of 13 studies involving AMPK activity (Thr172)
and overall, cancer-specific, or progression-free sur-
vival in various cancers, eight studies reported that
AMPK activation led to improved prognosis [42].
However, studies of gastric cancer and prostate cancer
have reported a link between pAMPK alpha1 and dis-
ease recurrence [42]. AMPK activation in breast cancer
reduces disease-specific and metastasis-free survival
[47]. Ovarian cancer has different clinical relationship
with the expression of AMPK subunits according to
histological subtype [26,53]. Therefore, there is a need
to compare AMPK activity and OCCC patient prog-
nosis.
In summary, we have identified 14 genes that are
importantly regulated during the transition phase of
endometriosis to OCCC. Furthermore, we demon-
strated that TSPAN1 is involved in endometriosis cell
growth through AMPK activation. Unlike in
endometriosis cells, the role of TSPAN1 is not carried
out via AMPK activity in OCCC cells. However, con-
sidering that AMPK activity in OCCC is considerably
high, it is predicted that if TSPAN1 and AMPK are
simultaneously suppressed, this will inhibit OCCC
growth. Therefore, this study has great significance in
discovering the role of TSPAN1 in the malignant
transformation of endometriosis into OCCC.
5. Conclusion
TSPAN1 was found to increase endometriosis cell
growth and invasion by promoting AMPK activity.
These results suggest that expression changes of
TSPAN1 and other DEGs occurred early in the malig-
nant transformation of endometriosis, showing the
potential for screening for high-risk endometriosis.
Moreover, our findings enable the development of
drugs that can aid in preventing the transformation of
endometriosis into malignant cancer by controlling
TSPAN1 levels and AMPK activity.
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Fig. S1. Venn diagram distribution of candidate genes
based on adjusted p-values.
Fig. S2. Immunohistochemical staining of TSPAN1 in
human small intestine tissue.
Fig. S3. Linear correlation analysis using scatter plots
of the six different two-group comparisons.
Fig. S4. Characteristics of the immortalized endome-
trial (6595, 6866_SV40) and endometriosis
(6045_SV40, 9585_SV40) cell lines.
Fig. S5. TSPAN1 increases cell growth but not cell
invasion in the TOV-21G stable cells.
Fig. S6. In GSE53012 analysis, TSPAN1 expression
was increased in cycling and chronic hypoxic condi-
tions in PC-3 and SKOV3, but not in WM793B.
Fig. S7. AMPK activity is high in OCCC and is
increased by ARID1A knockdown.
Table S1. Tabular data shows the fold change of 14
genes in 5 different two-group comparisons.
Table S2. STR profiling.
Table S3. TSPAN1 score of immunohistochemical
staining.
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